OncoCyte announces 1-for-20 reverse stock split

Oncocyte Corporation announced that the company will implement a 1-for-20 reverse stock split of the outstanding shares of its common stock. The reverse stock split will be effective at 5:00 p.m. Pacific time on July 24, 2023, and the company’s common stock will begin to trade on a post-split basis at the market open on July 25, 2023, under the company’s existing trading symbol “OCX“. The CUSIP number for the common stock following the reverse stock split will be 68235C206. The reverse stock split is part of the company’s plan to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Stock Market The reverse stock split was approved by the company’s shareholders at a Special Meeting of Shareholders held on July 24, 2023, which authorized the Company to effect the reverse stock split at the discretion of the company’s Board of Directors within certain parameters approved by the shareholders. The final split ratio was subsequently approved by the Company’s Board of Directors at a meeting held on July 24, 2023.